Skip to main content
Premium Trial:

Request an Annual Quote

Genomatix, USU Seek to Use NGS to Find Prostate Cancer Prognostic Markers

Premium

Genomatix Software, the Uniformed Service University of the Health Sciences, and the Henry M. Jackson Foundation for the Advancement of Military Medicine will collaborate on a project to use next-gen sequencing to help identify biomarkers for prostate cancer prognostics.

The goal of the collaboration is to identify biomarkers that can be used to help predict the outcome of prostate cancer patients at the time of diagnosis, which is currently difficult to do.

The project will combine USUHS' Center for Prostate Diseases Research's translational research resources and expertise with Genomatix's data-analysis software to identify novel androgen receptor-binding sites to analyze prostate cancer metastasis using model systems and clinical specimens.

"Next-generation sequencing opens a new dimension in biomarker research and will allow a finer grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring," Genomatix founder Thomas Werner said in statement.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.